Christopher Lee-Smith
Known title: Co-Founder, Head of Distrib.CIK: 0002008627
Christopher Lee-Smith's purchase track record
Christopher Lee-Smith has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 11/19/2025 | ARX | $197K | -21.0% | +24.7% | +11.9% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| ARX | ▲ Buy | Grant | 128,644 | $0 | 3/18/2026 | View on chart |
| ARX | ▲ Buy | Open Market | 14,700 | $197K | 11/19/2025 | View on chart |
| ARX | ▼ Sell | Other | 17,509,884 | — | 7/25/2025 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 12, 2026
ARX Valuation and Sales Focus Highlighted in Recent Articles
Recent Yahoo articles note that Accelerant Holdings is viewed as fully or fairly valued, with analysts emphasizing the importance of upcoming sales performance. The coverage also mentions a growing narrative around the company's growth prospects. Additionally, options market activity has been highlighted as potentially indicating heightened interest in the stock. The stock currently trades near the average analyst target of $19.11 and within its 52‑week range.
ARX Valuation and Sales Focus Highlighted in Recent Articles. Recent Yahoo articles note that Accelerant Holdings is viewed as fully or fairly valued, with analysts emphasizing the importance of upcoming sales performance. The coverage also mentions a growing narrative around the company's growth prospects. Additionally, options market activity has been highlighted as potentially indicating heightened interest in the stock. The stock currently trades near the average analyst target of $19.11 and within its 52‑week range.